Ponesimod for the treatment of relapsing multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ponesimod for the treatment of relapsing multiple sclerosis

Published:2020-08-18 Issue:16 Volume:21 Page:1955-1964
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Baldin Elisa¹^ORCID,Lugaresi Alessandra²³^ORCID

Affiliation:

1. Epidemiology and Biostatistics Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

2. Dipartimento di Scienze Biomediche e Neuromotorie, Università UOSI Riabilitazione Sclerosi Multipla, di Bologna, Bologna, Italy

3. UOSI Riabilitazione Sclerosi Multipla, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1799977

Reference67 articles.

1. Multiple sclerosis

2. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update

3. Environmental factors in multiple sclerosis

4. MSIF. Atlas of MS 2013; 2013.

5. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?;Current Neuropharmacology;2024-07

2. PET Imaging of Sphingosine-1-Phosphate Receptor 1 with [18F]TZ4877 in Nonhuman Primates;2024-05-30

3. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-23

4. Schwangerschaft und Stillzeit bei Frauen mit Multipler Sklerose;Der Nervenarzt;2024-02-23

5. Insight into modulators of sphingosine-1-phosphate receptor and implications for cardiovascular therapeutics;Journal of Drug Targeting;2024-02-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3